Proinflammatory cytokines and glial cells: Their role in neuropathic pain

  • Joyce A. DeLeo
  • Raymond W. Colburn
Part of the Progress in Inflammation Research book series (PIR)

Abstract

Neuropathic pain, or chronic pain due to nerve injury, is a prevalent condition for which currently there is no effective treatment. These neuropathic pain syndromes include deafferentation pain, diabetic, cancer and ischemic neuropathies, phantom limb pain, trigeminal neuralgia, postherpetic neuralgias and nerve injury caused by surgery or trauma [1]. Neuropathic pain is not only chronic and intractable, it is debilitating and causes extreme physical, psychological and social distress. In an effort to provide even temporary relief, narcotics (opioids) are often used inappropriately and in excess. Even if opioids provide some initial relief, tolerance and physical dependence are major limitations to their continued use. Clearly, development of non-opioid and non-addictive treatments for neuropathic pain would offer tremendous benefit to chronic pain patients. Our laboratory has focused on understanding mechanisms that lead to neuropathic pain. This knowledge may then translate into development of new, effective approaches for treatment and even prevention of chronic pain syndromes.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Loeser JD. (1990) Peripheral nerve disorders (peripheral neuropathies). In: Bonica J (ed): The management of pain,. 2nd ed. Lea and Febiger, Pennsylvania, 211–219Google Scholar
  2. 2.
    DeLeo JA, Coombs DW (1991) Autotomy and decreased substance P following peripheral cryogenic nerve lesion. Cryobiol 28: 460–466CrossRefGoogle Scholar
  3. 3.
    DeLeo JA, Coombs DW, Willenbring SW, Colburn RW, Fromm C, Wagner R, Twitchell BB (1994) Characterization of a neuropathic pain model: Sciatic cryoneurolysis in the rat. Pain 56: 9–16.PubMedCrossRefGoogle Scholar
  4. 4.
    Willenbring S, DeLeo JA, Coombs DW (19 94) Differential behavioral outcomes in the sciatic cryoneurolysis model of neuropathic pain in rats. Pain 58: 135–140PubMedCrossRefGoogle Scholar
  5. 5.
    Colburn RW, DeLeo JA, Rickman AJ, Yeager MP, Kwon P, Hickey WF (1997) Dissociation of microglial activation and neuropathic pain behaviors following peripheral nerve injury in the rat. J Neuroimmunol 79: 163–175PubMedCrossRefGoogle Scholar
  6. 6.
    Colburn RW, DeLeo JA, Rickman AJ (1997) The effect of site vs. type of nerve injury on glial activation, spinal cytokine expression and behavior in the rat. Soc for Neurosci Abstr, New Orleans, LAGoogle Scholar
  7. 7.
    Bennett GJ, Xie YK (1988) A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 33: 87–107PubMedCrossRefGoogle Scholar
  8. 8.
    Kim SH, Chung JM (1992) An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 50: 355–363PubMedCrossRefGoogle Scholar
  9. 9.
    Woolf CJ, Allchorne A, Safieh-Garabedian B, Poole S (1997) Cytokines, nerve growth factor and inflammatory hyperalgesia: the contribution of tumour necrosis factor-a. Brit J Pharm 121: 417–424CrossRefGoogle Scholar
  10. 10.
    Rothwell NJ (1991) Functions and mechanisms of interleukin-1 in the brain. Trends Pharmacol Sci 12: 430–436PubMedCrossRefGoogle Scholar
  11. 11.
    Fontana A, Kristensen F, Dubs R, Gemsa D, Weber E (1992) Production of Joyce A. DeLeo and Raymond W. Colburn prostaglandin E and an interleukin-1 like factor by cultured astrocytes and C6 glioma cells. J Immunol 129: 2413–2419Google Scholar
  12. 12.
    Giulian D, Baker TJ, Shih L-CN, Lachman LB (1986) Interleukin-1 of the central nervous system is produced by ameboid microglia. J Exp Med 164: 594–604PubMedCrossRefGoogle Scholar
  13. 13.
    Farrar WL, Hill JM, Harel-Bellan A, Vinocour M (1987) The immunological brain. Immunol Rev 100: 361–378PubMedCrossRefGoogle Scholar
  14. 14.
    Lechan RM, Toni R, Clark BD, Cannon JG, Shaw AR, Dinarello CA, Reichlin S (1990) Immunoreactive interleukin-1(3 localization in the rat forebrain. Brain Res 514: 135–140PubMedCrossRefGoogle Scholar
  15. 15.
    Sheeran P, Hall GM (1997) Cytokines in anaesthesia. Brit J Anaes 78: 201–219CrossRefGoogle Scholar
  16. 16.
    Rotshenker S, Aamar S, and Barak V (1992) Interleukin-1 activity in lesioned peripheral nerve. J Neuroimmunol 39: 75–80PubMedCrossRefGoogle Scholar
  17. 17.
    Watkins LR, Wiertelak EP, Goehler LE, Smith KP, Martin D, Maier SF (1994) Characterization of cytokine-induced hyperalgesia. Brain Res 654: 15–26PubMedCrossRefGoogle Scholar
  18. 18.
    Oka T, Aou S, Hori T (1993) Intracerebroventricular injection of interleukin-1(3 induces hyperalgesia in rats. Brain Res 624: 61–68PubMedCrossRefGoogle Scholar
  19. 19.
    Oka T, Aou S, Hori T (1994) Intracerebroventricular injection of interleukin-113 enhances nociceptive neuronal responses of trigeminal nucleus caudalis in rats. Brain Res 656: 236–244PubMedCrossRefGoogle Scholar
  20. 20.
    Oka T, Oka K, Hosoi M, Aou S, Hori T (1995) The opposing effects of interleukin-113 microinjected into the preoptic hypothalamus on nociceptive behavior in rats. Brain Res 700: 271–278PubMedCrossRefGoogle Scholar
  21. 21.
    Won C, Park HJ, Shin HC (1995) Interleukin-113 facilitates afferent sensory transmission in the primary somatosensory cortex of anesthestized rats. Neurosci Letters 201: 255–258CrossRefGoogle Scholar
  22. 22.
    Patterson PH, Nawa H (1993) Neuronal differentiation factors/cytokines and synaptic plasticity. Cell 72: 123–137PubMedCrossRefGoogle Scholar
  23. 23.
    Taga T (1996) gp130, a shared signal transducing receptor component for hematopoietic and neuropoietic cytokines. J Neurochem 67: 1–10PubMedCrossRefGoogle Scholar
  24. 24.
    Kiefer R, Lindholm, D, Kreutzberg, G (1993) Interleukin-6 and transforming growth factor-131 mRNAs are induced in rat facial nucleus following motorneuron axotomy. Eur J Neurosci 5: 775–781PubMedCrossRefGoogle Scholar
  25. 25.
    Murphy PG, Grodin J, Altares M, Richardson PM (1995) Induction of interleukin-6 in axotomized sensory neurons. J Neurosci 15: 5130–5138PubMedGoogle Scholar
  26. 26.
    Bolin LM, Verity AN, Silver JE, Shooter EM, Abrams JS (1995) Interleukin-6 production in schwann cells and induction in sciatic nerve injury. J Neurochem 64: 850–858PubMedCrossRefGoogle Scholar
  27. 27.
    Frei K, Malipiero UV, Leist TP, Zinkernagel RM, Schwab ME, Fontana A (1989) On the cellular source and function of interleukin-6 produced by the central nervous system. Eur J Immunol 19: 689–694PubMedCrossRefGoogle Scholar
  28. 28.
    Le J, Vilcek J (1989) Interleukin-6: a multifunctional cytokine regulating immune reactions and the acute phase protein response. Lab Invest 61: 588–602PubMedGoogle Scholar
  29. 29.
    Fattori E, Lazzaro D, Musiani P, Modesti A, Alonzi T, Ciliberto G (1995) IL-6 expres-sion in neurons of transgenic mice causes reactive astrocytosis and increase ramified microglial cells but no neuronal damage. Eur J Neurosci 7: 2441–2449PubMedCrossRefGoogle Scholar
  30. 30.
    DeLeo JA and RW Colburn (1996) The role of cytokines in nociception and chronic pain. In: Weinstein J, Gordon S (eds): Low back pain: A scientific and clinical overview. American Academy of Orthopaedic Surgeons, Illinois, 163–186Google Scholar
  31. 31.
    Oka T, Oka K, Hosoi M, Hori T (1995) Intracerebroventricular injection of interleukin6 induces thermal hyperalgesia in rats. Brain Res 692: 123–128PubMedCrossRefGoogle Scholar
  32. 32.
    DeLeo JA, Colburn RW, Nichols M, Malhotra A (1996) Interleukin (IL)-6 mediated hyperalgesia/alloydnia and increased spinal IL-6 in a mononeuropathy model in the rat. J Interferon and Cytokine Res 16: 695–700CrossRefGoogle Scholar
  33. 33.
    Qui Z, Parson KL, Gruol DL (1995) Interleukin-6 selectively enhances the intracellular calcium response to NMDA in developing CNS neurons. J Neurosci 15: 6688–6699Google Scholar
  34. 34.
    Meller ST, Gebhart GF (1993) Nitric oxide (NO) and nociceptive processing in the spinal cord. Pain 52: 127–136PubMedCrossRefGoogle Scholar
  35. 35.
    Davar G, Jama A, Deykin A, Vos B, Maciewicz R (1991) MK-801 blocks the development of thermal hyperalgesia in a rat model of experimental painful neuropathy. Brain Res 553: 327–330PubMedCrossRefGoogle Scholar
  36. 36.
    Price DD, Mao J, Frenk H, Mayer DJ (1994) The N-methyl-D-aspartate receptor antagonist dextromethorphan selectively reduces temporal summation of second pain in man. Pain 59: 165–174.PubMedCrossRefGoogle Scholar
  37. 37.
    Beutler B, Greenwald D, Hulmes JD, Chang M, Pan YC, Mathison J, Ulevitch R, Cera-mi A (1985) Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature 316: 552–554PubMedCrossRefGoogle Scholar
  38. 38.
    Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B (1975) An endotoxininduced serum factor that causes necrosis of tumors. Proc Natl Acad Sci 72: 3666–3669PubMedCrossRefGoogle Scholar
  39. 39.
    Tsujimoto M, Vilcek J (1986) Tumor necrosis factor receptors in HeLa cells and their regulation by interferon-gamma. J Biol Chem 261: 5384–5388PubMedGoogle Scholar
  40. 40.
    Smith CA, Davis T, Anderson D (1990) A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science 248: 1019–1023PubMedCrossRefGoogle Scholar
  41. 41.
    Loetscher H, Pan YC, Lahm HW (1990) Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor. Cell 61: 351–359PubMedCrossRefGoogle Scholar
  42. 42.
    Englemann H, Aderka D, Rubinstein M, Rotman D, Wallach D (1989) A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem 264: 11974–11980Google Scholar
  43. 43.
    Olsson I, Lantz M, Nilsson E (1989) Isolation and characterization of a tumor necrosis factor binding protein from urine. Eur J Haematol 42: 270–275PubMedCrossRefGoogle Scholar
  44. 44.
    Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, Ettlinger RE, Cohen S, Koopman WJ, Mohler K et al (1997) Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. New Eng J Med 337: 141–147PubMedCrossRefGoogle Scholar
  45. 45.
    Koller H, Thiem K, Siebler M (1996) Tumour necrosis factor-a increases intracellular Ca2+ and induces a depolarization in cultured astroglial cells. Brain 119: 2021–2027PubMedCrossRefGoogle Scholar
  46. 46.
    Fine SM, Angel RA, Perry SW, Epstein LF, Rothstein JD, Dewhurst S, Gelbard HA (1996) Tumor necrosis factor-a inhibits glutamate uptake by primary human astrocytes. J Biol Chem 271(26): 15303–15306PubMedCrossRefGoogle Scholar
  47. 47.
    Ding M, Hart RP, Jonakait FM (1995) Tumor necrosis factor-a induces substance P in sympathetic ganglia through sequential induction of Interleukin-1 and Leukemia Inhibitory Factor. J Neurobiol 28: 445–454PubMedCrossRefGoogle Scholar
  48. 48.
    DeLeo JA, Colburn RW, Rickman AJ (1997) Cytokine and growth factor immunohistochemical spinal profiles in two animal models of mononeuropathy. Brain Res 759: 50–57PubMedCrossRefGoogle Scholar
  49. 49.
    Hickey, WF, Kimura H (1988) Perivascular microglia are bone marrow derived and present antigen in vivo. Science 239: 290–292PubMedCrossRefGoogle Scholar
  50. 50.
    Streit WJ, and Kincaid-Colton CA (1995) The brain’s immune system. Scientific Amer Nov: 54–61Google Scholar
  51. 51.
    Meller ST, Dykstra C, Grsybicki, Murphy S, Gebhart GF (1994) The possible role of glia in nociceptive processing and hyperalgesia in the spinal cord of the rat. Neuropharm 33: 1471–1478CrossRefGoogle Scholar
  52. 52.
    Garrison CJ, Dougherty PM, Kajander KC, Carlton SM (1991) Staining of glial fibrillary acidic protein (GFAP) in lumbar spinal cord increases following a sciatic nerve constriction injury. Brain Res 565: 1–7PubMedCrossRefGoogle Scholar
  53. 53.
    Hajos F, Csillik B, Knyihar-Csillik E (1990) Alterations in glial fibrillary acidic protein immunoreactivity in the upper dorsal horn of the rat spinal cord in the course of trans-ganglionic atrophy and regenerative proliferation. Neurosci Lett 17: 8–13CrossRefGoogle Scholar
  54. 54.
    Tetzlaff W, Graeber MB, Bisby MA, Kreutzberg GW (1988) Increased glial fibrillary protein synthesis in astrocytes during retrograde reaction of the rat facial nucleus. Glia 1: 90–95PubMedCrossRefGoogle Scholar
  55. 55.
    Norris JG, Benveniste EN (1993) Interleukin-6 production by astrocytes: Induction by the neurotransmitter norepinephrine. J Neurosci 45:137–146Google Scholar
  56. 56.
    Chung JM, Leem JW, Kim SH (1992) Somatic afferent fibers which continuously discharge after being isolated from their receptors. Brain Res 599: 29–33PubMedCrossRefGoogle Scholar
  57. 57.
    Korenman EMD, Devor M (1981) Ectopic adrenergic sensitivity in damaged peripheral nerve axons in the rat. Exp Neurol 72: 63–81.PubMedCrossRefGoogle Scholar
  58. 58.
    McLachlan EM, Janig W, Devor M, Michaelis M (1993) Peripheral nerve injury triggers noradrenergic sprouting within the dorsal root ganglia. Nature 363: 543–545PubMedCrossRefGoogle Scholar
  59. 59.
    Sato J, Perl ER (1993) Adrenergic excitation of cutaneous pain receptors induced by peripheral nerve injury. Science 251:1608–1610CrossRefGoogle Scholar
  60. 60.
    Ventimiglia R, Green MI, Geller HM (1987) Localization of f3-adrenergic receptors on differentiated cells of the central nervous system in culture. Proc Natl Acad Sci 84: 5073–5077PubMedCrossRefGoogle Scholar
  61. 61.
    Furukawa S, Furukawa Y, Satoyoshi E, Hayashi K (1987) Regulation of nerve growth factor synthesis/secretion by catecholamine in cultured mouse astroglial cells. Biochem Biophys Res Commun 147: 1048–1054PubMedCrossRefGoogle Scholar
  62. 62.
    Frohman EM, Vayuvegula B, van den Noort S, Gupta S (1988) Norepinephrine inhibits gamma-interferon-induced MHC class II (Ia) antigen expression on cultured brain astrocytes. J Neuroimmunol 17: 89–101PubMedCrossRefGoogle Scholar
  63. 63.
    Kashiba H, Senba E, Kawai Y, Ueda Y, Tohyama (1992) Axonal blockade induces the expression of vasoactive intestinal peptide and galanin in rat dorsal root ganglion neurons. Brain Res 577: 19–28PubMedCrossRefGoogle Scholar
  64. 64.
    Sontheimer H, Black JA, Waxman SG (1996) Voltage-gated Na+ channels in glia: properties and possible functions. Trends Neurosci 19: 325–331PubMedCrossRefGoogle Scholar
  65. 65.
    Steinhauser C, Gallo V (1996) News on glutamate receptors in glial cells. Trends Neurosci 19: 339–345PubMedCrossRefGoogle Scholar
  66. 66.
    Glabinshi AR, Balasingam V, Tani M, Kunket SL, Strieter RM, Yong VW, Ransohoff RM (1996) Chemokine monocyte chemoattractant protein-1 is expressed by astrocytes after mechanical injury to the brain. J Immunol 156: 4363–4368Google Scholar
  67. 67.
    Hurwitz AA, Lyman WD, Berman JW (1995) Tumor necrosis factor alpha and transforming growth factor beta upregulate astrocyte expression of monocyte chemoattractant protein-1. J Neuroimmunol 57: 193–198PubMedCrossRefGoogle Scholar
  68. 68.
    Garrison CJ, Dougherty PM, Carlton SM (1994) GFAP expression in lumbar spinal cord of naive and neuropathic rats treated with MK-801. Exp Neurol 129: 237–243PubMedCrossRefGoogle Scholar
  69. 69.
    Watkins LR, Marin D, Ulrich P, Tracey KJ, Maier SF (1997) Evidence for the involvement of spinal cord glia in subcutaneous formalin induced hyperalgesia in the rat. Pain 71: 225–235PubMedCrossRefGoogle Scholar
  70. 70.
    Xiao WH, Wagner R, Myers RR, Sorkin LS (1996) TNF-a applied to the sciatic nerve trunk elicits background firing in nociceptive primary afferent fibers. 8th World Congress on Pain. Vancouver, BC, CanadaGoogle Scholar
  71. 71.
    Wagner R, Myers RR (1996) Endoneurial injection of TNF alpha produces neuropathic behaviors. Neuro Report 7: 2897–2901Google Scholar
  72. 72.
    Bennett GJ, Laird JMA (1992) Central changes contributing to neuropathic hyperalgesia. In: Willis, Jr. WD (ed): Hyperalgesia and allodynia. Raven Press, New York, 305–310Google Scholar
  73. 73.
    Wagner R, DeLeo JA, Coombs DW, Colburn RW, Willenbring S, Fromm C (1993) Spinal dynorphin bilaterally increases in a rat neuropathic pain model. Brain Res 629: 323–326PubMedCrossRefGoogle Scholar
  74. 74.
    Wall PD (1983) Alterations in the central nervous system after deafferentation: Connectivity control. In: Bonica J (ed): Advances in pain research and therapy. Raven Press, New York, 677–689Google Scholar
  75. 75.
    Lewin GR, Rueff A, Mendell LM (1994) Peripheral and central mechanisms of NGFinduced hyperalgesia. Eur J Neurosci 6: 1903–1912PubMedCrossRefGoogle Scholar
  76. 76.
    Strijbos P, Rothwell NJ (1995) Interleukin-43 attenuates excitatory amino acid-induced neurodegeneration in vitro: involvement of nerve growth factor. J Neurosci 15: 3468–3474PubMedGoogle Scholar
  77. 77.
    Lewin GR, Mendell LM (1993) Nerve growth factor and nociception. TINS 16: 353–365PubMedGoogle Scholar

Copyright information

© Springer Basel AG 1999

Authors and Affiliations

  • Joyce A. DeLeo
    • 1
  • Raymond W. Colburn
    • 1
  1. 1.Departments of Anesthesiology and PharmacologyDartmouth-Hitchcock Medical CenterLebanonUSA

Personalised recommendations